Calithera Biosciences is a clinical-stage precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations. Co.'s product candidate, CB-280, is an oral inhibitor of arginase, developed for the treatment of cystic fibrosis. Co. has also identified CB-668, an orally administered inhibitor of the immune-suppressive enzyme IL4I1. An additional arginase inhibitor, INCB001158, was discovered by Co. and is being developed by Incyte Corporation for oncology and hematology indications. Co. has developed CB-708, a selective, orally-bioavailable small molecule inhibitor of CD73. We show 35 historical shares outstanding datapoints in our coverage of CALA's shares outstanding history.
Understanding the changing numbers of CALA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like CALA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching CALA by allowing them to research CALA shares outstanding history
as well as any other stock in our coverage universe. |
Free CALA Email Alerts:
Video: Shares Outstanding Importance
